Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.59 |
| ▸ | DRD3 | P35462 | 12/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 9/20 | 0.54 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14715752 | 1.00 | HTR2A (0.59) | HTR2ADRD3EPHX2DRD2SLC6A12 | |
| SCHEMBL3966402 | 0.90 | DRD2 (0.58) | HTR2ADRD3EPHX2DRD2SLC6A12 | |
| SCHEMBL3069359 | 0.88 | EPHX2 (0.74) | HTR2ADRD3EPHX2DRD2 | |
| SCHEMBL3069356 | 0.88 | EPHX2 (0.74) | HTR2ADRD3EPHX2DRD2 | |
| SCHEMBL3079469 | 0.87 | PRKAA2 (0.60) | HTR2ADRD3DRD2HRH3PRKAA2 | |
| SCHEMBL3081406 | 0.87 | DRD3 (0.60) | HTR2ADRD3DRD2 | |
| SCHEMBL14715784 | 0.87 | DRD3 (0.60) | HTR2ADRD3DRD2 | |
| SCHEMBL4081506 | 0.87 | PRKAA2 (0.60) | HTR2ADRD3DRD2HRH3PRKAA2 | |
| SCHEMBL3067409 | 0.87 | DRD3 (0.57) | HTR2ADRD3DRD2 | |
| SCHEMBL14715694 | 0.87 | DRD3 (0.57) | HTR2ADRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | claimed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | claimed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | claimed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | HTR2A 565/4885DRD3 71/4885EPHX2 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.